Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (104)	2/8/2005 11:46:50 AM
From: keokalani'nui	Respond to of 588

Research and Markets : Parkinsons Disease Drug Revenues Grew 17% Across Seven Major Markets, Driven by Increasingly Important Role of Dopamine Agonist Class Tuesday February 8, 9:10 am ET DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 8, 2005--Research and Markets (http://www.researchandmarkets.com/reports/c12599) has announced the addition of Commercial Insight: Parkinsons Disease - Increased Focus on Earlier Treatment and Managing Levodopa Complications Will Drive Market Growth to their offering Despite the growth of generic levodopa products, Parkinsons disease drug revenues grew an impressive 17% across the seven major markets to reach $1.7 billion in 2003, driven by the increasingly important role of the dopamine agonist class. Growing evidence for the role of the dopamine agonists as first-line therapy has ensured strong growth of this class, which now account for over half of the global market. However, with several generic dopamine agonists and novel drugs expected to launch over the next decade, current players must focus on new strategies, including reformulations. With a growth rate of 33.5% between 2002-03, the catechol-O-methyltransferase inhibitor class has witnessed the greatest year-on-year revenue growth, driven by Novartiss Comtan and the company's ability to position the drug as a treatment for niche patient cohorts. The recent launch of Stalevo will ensure the continued strong growth of this class. Marketed therapies work primarily to treat the symptoms of Parkinsons disease. However, several compounds in development have demonstrated neuroprotective properties and have the potential to revolutionize the market. Nevertheless, reaching the market and providing convincing clinical evidence of this remains a huge challenge. However, several patent expiries and product launches are set to send the market through a period of change. (snip) biz.yahoo.com